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    Advanced glycation end-products (AGEs) are formed by non-enzymatic reaction between reducing sugar 
and protein. AGEs play important roles in pathogenesis of diabetic, aging complications, endothelial 
dysfunction and neurological diseases such as the Alzheimer’s disease. Therefore compounds that prevent 
the glycation reaction are purported to have therapeutic effect on patients with diabetes and age-related 
complication. In this study, the Human serum albumin at concentration of 10 mg/ml was incubated in PBS 
with 40 mM Glucose, and in different concentrations of Naloxone (25,100,250µM) for 42 days at 37˚C. 
HSA with no additives and with Glucose 40mM were incubated as control and as glycated sample, 
respectively. Following the incubation, the samples were prepared for Circular Dichroism, Fluorescence and 
absorbance techniques. It was shown different Naloxone concentration can prevent Human serum albumin 
glycation. 
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INTRODUCTION 
    Diabetes mellitus is known as metabolic 
disorders and is manifested by 
hyperglycemia[1].The none enzymatic glycation 
of protein is a process which is happened in 
patient with hyperglycemia  ,it causes a series of 
pathophysiological changes and different 
disease[2]. None enzymatic glycation of protein 
subdivided into two steps: early and late. In the 
early phase, reducing sugar react with the free 
amino group of protein, forming Schiff base and 
Amadori products. In the late phase in order to 
formation advanced glycation end products 
(AGE), Amadori more rearrangements to produce 
AGE products [3]. AGEs have an important effect 
on the development of atherosclerosis, 
neurological disorder; also AGE causes damage 
to eyes, kidneys joint and they are responsible for 
aging and tissue damage [4-6]. Non enzymatic 
glycation of serum albumin occurs at multiple 
sites, in vivo. Glucose gets attached to lys-199, 
lys-281, lys-439, and lys-525 as well as to some 
other lysine residues [7]. Naloxone is a drug that 
is used as an opioid antagonist; it uses specifically 
to block the side effects of opiate overdose and 
counteract depression of the CNS and respiratory 
system [8]. Naloxone is made up of thebaine that 
is obtained of plant papaver somniferous [9]. 
Compounds that inhibit the formation of AGEs 
are purported to have therapeutic potentials in 
patients with diabetes and age-related diseases. 
Researches show that many agents can prevent 
AGE formation; it has been shown 
Aminoguanidine, Zea mays, garlic, pepper , 
ginger and some other plant exteract have good 
antioxidant as well as antiglycation potential [10- 
12].in present study we have decided to examine 
the effect of Naloxone on human serum albumin 
glycation. 
 
MATERIALS AND METHODS 
Materials 
     Human serum albumins, sodium bicinchoninic 
acid were purchased from Sigma .The membrane 
filters (0.2 µm pore size, 25mm in diameter) and 
dialysis tubing (cut-off 10,000MW) were 
obtained from Whatman (UK). 2, 4, 6-
trinitrobenzene sulfonic acid (TNBSA) were 
acquired from Fluka. Papaverine was received 
from pharmacy. All others materials were 




purchased from Merck (Germany). All solutions 
were prepared with deionized water. 
In vitro glycation of HSA 
    HSA 10mg/ml were incubated in PBS 50 mM 
(pH7.4) containing glucose 40 mM and different 
concentration of Naloxone 25,100,250µM for 42 
days at 37˚C. In addition, HSA were incubated 
with and without glucose as glycated (H+G 
sample) and as control (H sample), respectively 
After the 42 days, the samples were dialyzed 
extensively against PBS at 4˚C and stored at -
20˚C [13].  
AGE-specific fluorescence 
    The AGE-fluorescence of all samples (1mg/ml) 
were obtained on a Cary Eclipse fluorescence 
spectrophotometer at Ex/Em (380/390-540 nm). 
Each point represents the mean of three 
independent experiments [14]. 
Statistical analysis 
    The results were expressed as Mean ± SEM. 
The significance of the positive effect of 
Papaverine was determind by a chi-square test 




     The far-UV CD spectrum of HSA is 
recognized by the presence of two strong negative 
bands at 208 and 222 nm, which represent the 
helical characteristics of HAS(see H sample in 
Fig,1). As seen in Fig. 1, there is a loss of helical 
structure as shown by a decrease in the negative 
ellipticity at 208 and 222 nm due to the 42-day 
incubation of glucose with HSA (H+G) compared 
to the control (H). HSA in the presence of glucose 
and different Naloxone concentration show 
significantly more negative ellipticity values at 
208 and 222 nm on the 42 day of incubation in 
comparison with glycated sample (H+G). Fig. 3 
and 4 show the enhancement in fluorescence 
intensity in glycated HSA (H+G) compared to the 
control HSA (H). The results indicate that HSA 
incubated with glucose and different Naloxone 
concentration show a decrease in fluorescence 




Figure 1. Circular Dichroism spectra of all samples that were incubated for 42 days in PBS 50 mM, pH7.4 at 37˚C.H, G and 














Figure 2. AGE fluorescence spectra of all samples that were incubated for 42 days in PBS50 mM, pH7.4 at 37˚C Ex/Em 





Figure 3. Maximum AGE fluorescence spectra of all samples that were at 420 nm. H, G and N are the same as Figure1. 














Figure 4. Naloxone can get attach to halothane site in human serum albumin [15] 
 
As it is shown in figure 3, previous study has 
shown that Naloxone has ability to interact with 
human serum albumin. In accordance with earlier 
study Naloxone is connected to the halothane site 
in HSA [15].  
 
DISCUSSION 
    The AGEs are formed as the result of the 
Reducing sugars reaction with proteins [16]. 
Because of long life period and high 
concentration HSA in plasma; it is one of the 
most important targets for glycation reaction. 
Naloxone is made up of thebaine that is obtained 
of plant papaver somniferous. Naloxone prevents 
or reverses the effects of opioid including 
respiratory depression, sedation and hypotension.  
Also, Naloxone can reverse the psychotomimetic 
and dysphoric effects of agonist-antagonists, such 
as pentazocine [9]. An extensive change in the 
secondary structure of proteins takes place after 
the glycation process; it means glycation induces 
α-helix to β-sheet transition that is detectable with 
Circular Dichroism (CD)[18]. CD spectrum of 
HSA is characterized by present two strong 
negative bands at 208 and 222 nm in control(H 
sample) but in glycated sample (H+G) these two 
negative band have decreased as a result of 
glycation [3]. In comparison with glycated sample 
(H+G), samples which contain HSA with glucose 
and Naloxone show enhance in negative band.  
The fluorescence, as an index of advanced 
glycation, increased linearly over time for HSA 
incubated with reducing sugar; it means glycated 
protein has fluorescence property [17, 19,20,21]. 
On the other hand at those Figures, samples with 
HSA plus glucose and Naloxone show decrease 
in fluorescence feature compared with glycated 
sample (H+G).we think HSA in present 
Naloxone can be protected against Glycation 
reaction because it prevent attachment between 
HSA and sugar [15].    
 
CONCLUSION 
    The main goal of this study was to examine 
antiglycation activity of Naloxone on pathway of 
AGEs formation and this data were acquired by 
Circular Dichroism, fluorescence. Circular 
Dichroism and fluorescence have confirmed in 
samples which have HSA plus Naloxone and 
glucose, Naloxone inhibit reaction between HSA 
and glucose. So it seems that it has antiglycation 
activity. As previous study has shown Naloxone 
get attach to halothane site in HSA [15].  
It seems Naloxone through attachment to HSA 
prevent glycation reaction between HSA and 
glucose. Overally it can be concluded that 
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Naloxone can inhibit glycation reaction so it is 
an AGE inhibitor. Finally it can be summarized 
that Naloxone inhibits glycation of HSA and 
leads to decrease AGE formation. 
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